Table of Contents
Understanding Pediatric Diabetes: A Growing Health Challenge
Diabetes management in children and adolescents represents one of the most challenging aspects of pediatric endocrinology. The condition affects millions of young people worldwide, requiring constant vigilance, multiple daily interventions, and a delicate balance between maintaining optimal blood glucose control and preserving quality of life. For families navigating this complex landscape, the burden of traditional insulin therapy—particularly the need for multiple daily injections—can be overwhelming both physically and emotionally.
The psychological impact of needle-based insulin delivery on children cannot be overstated. Many young patients develop needle phobia, leading to treatment avoidance, poor adherence, and ultimately suboptimal glycemic control. Parents often describe the daily struggle of administering injections to resistant children, creating stress and anxiety that permeates family dynamics. This reality has driven researchers and pharmaceutical companies to explore alternative delivery methods that could reduce the invasiveness of diabetes management while maintaining therapeutic efficacy.
Enter Afrezza, an inhaled insulin formulation that has been available for adults since 2014 and is now on the cusp of potentially transforming pediatric diabetes care. Afrezza, a rapid-acting inhaled human insulin, was first approved by the FDA in June 2014 for adults aged 18 years and older with diabetes mellitus. The prospect of a needle-free insulin option for children has generated considerable excitement among healthcare providers, patients, and families alike.
What is Afrezza? Understanding Inhaled Insulin Technology
Afrezza represents a significant innovation in insulin delivery technology. Unlike traditional injectable insulins that must be administered subcutaneously via syringe, pen, or pump, Afrezza is delivered directly to the lungs through a small, portable inhaler. This unique delivery mechanism offers several potential advantages, particularly for pediatric populations who may struggle with the physical and emotional challenges of repeated injections.
The Technosphere Technology Behind Afrezza
The key to Afrezza’s effectiveness lies in its proprietary Technosphere technology. This innovative system uses specially engineered microparticles that carry insulin molecules deep into the lungs, where they can be rapidly absorbed into the bloodstream. “The average Technosphere particle is about 2-2.5 µm which is in the middle of the respirable range,” explains Marshall Grant, PhD, MSc, Executive Director, Clinical Pharmacology & Research for MannKind Corporation. This precise particle size ensures optimal delivery to the alveoli, the tiny air sacs in the lungs where gas exchange—and in this case, insulin absorption—occurs.
The Technosphere particles are designed to dissolve rapidly upon contact with the moisture in the lungs, releasing the insulin for quick absorption into the bloodstream. This mechanism allows for a rapid onset of action that closely mimics the body’s natural insulin response to meals, making it particularly suitable for controlling postprandial (after-meal) blood glucose spikes.
How Afrezza Differs from Injectable Rapid-Acting Insulins
While Afrezza serves the same fundamental purpose as injectable rapid-acting insulin analogs like insulin aspart, insulin lispro, and insulin glulisine—controlling blood glucose levels around mealtimes—its pharmacokinetic profile offers some distinct characteristics. The pulmonary route of administration allows insulin to enter the bloodstream more directly than subcutaneous injection, potentially offering faster onset and offset of action.
This rapid pharmacokinetic profile may provide more physiologic insulin coverage for meals, potentially reducing the risk of both hyperglycemia immediately after eating and delayed hypoglycemia several hours post-meal. For children and adolescents whose eating patterns can be unpredictable and whose activity levels vary considerably throughout the day, this flexibility could represent a meaningful clinical advantage.
It’s important to note that Afrezza is designed to replace only mealtime (bolus) insulin, not basal insulin. Patients using Afrezza still require a long-acting basal insulin to maintain baseline glucose control between meals and overnight. This basal-bolus approach remains the standard of care for intensive insulin therapy in both type 1 and type 2 diabetes.
The INHALE-1 Study: Groundbreaking Research in Pediatric Populations
The potential expansion of Afrezza to pediatric patients is supported by data from the INHALE-1 clinical trial, a landmark study that represents the most comprehensive evaluation of inhaled insulin in children and adolescents to date. The sBLA submission was supported by data from randomized, open-label, phase 3 INHALE-1 study (ClinicalTrials.gov Identifier: NCT04974528), which evaluated Afrezza in pediatric patients aged 4 to 17 years with type 1 or 2 diabetes mellitus. Study participants (N=230) were randomly assigned 1:1 to receive Afrezza or rapid-acting insulin analog injections, alongside basal insulin.
Study Design and Methodology
The INHALE-1 trial was designed as a 26-week, open-label, randomized controlled study comparing Afrezza plus basal insulin to multiple daily injections of rapid-acting insulin analogs plus basal insulin. The open-label design—meaning both participants and researchers knew which treatment was being administered—was necessary given the obvious differences between inhaled and injected insulin delivery.
The primary endpoint was the change in hemoglobin A1c (HbA1c) levels after 26 weeks. Hemoglobin A1c is the gold standard measure of long-term glucose control, reflecting average blood glucose levels over approximately three months. The study aimed to demonstrate that Afrezza was “noninferior” to standard injectable insulin—meaning it was not meaningfully worse in terms of glucose control.
The trial also included a 26-week extension phase, during which all remaining participants who had been receiving multiple daily injections switched to Afrezza. This extension phase provided valuable additional safety data and allowed researchers to assess the long-term tolerability and effectiveness of inhaled insulin in pediatric patients.
Primary Efficacy Results: A Nuanced Picture
The primary efficacy results from INHALE-1 presented a complex picture that required careful interpretation. While an analysis of the full intent-to-treat population (ITT) found that the between-group difference in mean HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (0.435%), investigators noted this difference was driven by the variability of a single patient who did not adhere to the study protocol.
This finding highlights one of the challenges in clinical trial interpretation: how to handle protocol deviations and outlier data. In this case, a single non-adherent patient significantly influenced the overall results. When researchers conducted a modified intent-to-treat analysis excluding this patient, the picture changed substantially. Notably, in the modified ITT analysis, which excluded the single nonadherent patient, Afrezza was shown to be noninferior to multiple daily injections of rapid acting insulin analog (between-group difference: 0.370%).
This modified analysis demonstrated that Afrezza met the study’s primary endpoint of noninferiority, suggesting that inhaled insulin can provide comparable glycemic control to traditional injectable insulin in pediatric patients when used appropriately. The importance of adherence—a critical factor in any diabetes treatment regimen—was underscored by these results.
Safety Profile: Respiratory Function and Adverse Events
Given that Afrezza is delivered directly to the lungs, respiratory safety was a paramount concern in the pediatric trial. The INHALE-1 study included comprehensive pulmonary function testing to assess any potential impact on lung health. Results also showed comparable lung function parameters between treatment groups. Patients treated with Afrezza had a mean FEV1 of 2.901 liters (99.6% of predicted) at baseline and 2.934 liters (96.6% of predicted) at week 26, while those treated with multiple injections of rapid acting insulin analog had a mean FEV1 of 2.938 liters (102.3% of predicted) and 2.957 liters (98% of predicted), respectively.
FEV1 (forced expiratory volume in one second) is a key measure of lung function that indicates how much air a person can forcefully exhale in one second. The fact that FEV1 values remained stable and comparable between groups throughout the 26-week study period provided reassuring evidence that Afrezza did not adversely affect lung function in pediatric patients over this timeframe.
The most common adverse reactions associated with Afrezza in adult studies have been well-documented. Most common adverse reactions are hypoglycemia, cough, and throat pain or irritation. These side effects are generally mild and tend to diminish over time as patients become accustomed to the inhaled delivery method. The pediatric trial data will provide more specific information about the adverse event profile in younger populations.
Regulatory Pathway: FDA Review and Approval Timeline
The journey toward potential FDA approval of Afrezza for pediatric use represents a significant milestone in diabetes care. MannKind Corporation has announced the US Food and Drug Administration (FDA) acceptance of the supplemental biologics license application (sBLA) seeking approval for insulin human (Afrezza) Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes.1 · According to an October 13, 2025, release from the Company, the application is supported by results from the phase 3, 26-week, open-label INHALE-1 study and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2026.
The PDUFA date represents the deadline by which the FDA must complete its review and make a decision on the application. This regulatory milestone is eagerly anticipated by the diabetes community, as approval would mark a historic moment in diabetes treatment. If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy, representing a paradigm shift in how young people with diabetes manage their condition.
The FDA’s acceptance of the supplemental biologics license application for review indicates that the agency has determined the submission is sufficiently complete to warrant a substantive review. This is an important preliminary step, though it does not guarantee ultimate approval. The FDA will conduct a thorough evaluation of the efficacy and safety data, manufacturing processes, labeling, and other factors before making its final determination.
Clinical Advantages of Afrezza in Pediatric Diabetes Management
The potential benefits of inhaled insulin for children and adolescents extend beyond the obvious advantage of avoiding needles. While needle-free delivery is certainly a major selling point, the clinical and practical advantages of Afrezza encompass multiple dimensions of diabetes management.
Reducing Needle Anxiety and Improving Quality of Life
Needle phobia is a significant barrier to optimal diabetes management in pediatric populations. Many children develop anxiety around injections that can persist into adulthood, affecting not only their diabetes care but also their willingness to receive other necessary medical treatments. The psychological burden of multiple daily injections can lead to treatment avoidance, missed doses, and deteriorating glycemic control.
By eliminating the need for mealtime insulin injections, Afrezza has the potential to significantly reduce this psychological burden. Children can discreetly use the inhaler before meals without the pain, anxiety, or social stigma sometimes associated with injections. This could be particularly beneficial in school settings, where adolescents may feel self-conscious about their diabetes management in front of peers.
The impact on quality of life extends to families as well. Parents often describe the emotional toll of having to restrain young children for injections or negotiate with resistant adolescents about insulin administration. A needle-free option could transform these daily interactions, reducing family stress and conflict around diabetes management.
Rapid Onset of Action for Postprandial Glucose Control
The pharmacokinetic profile of Afrezza offers potential advantages for controlling post-meal blood glucose excursions. The rapid absorption of insulin through the lungs allows for a quick onset of action that may more closely mimic the body’s natural insulin response to food intake. This can be particularly valuable for managing the sharp glucose spikes that often occur after meals, especially those high in rapidly absorbed carbohydrates.
For children and adolescents, whose eating patterns may be less predictable than adults, the rapid onset and offset of Afrezza could provide more flexibility. If a child decides not to finish a meal or eats less than anticipated, the shorter duration of action may reduce the risk of delayed hypoglycemia compared to longer-acting injectable rapid-acting analogs.
Potential for Improved Treatment Adherence
Adherence to insulin therapy is a persistent challenge in pediatric diabetes management, particularly during adolescence when rebellion against parental authority and desire for independence can lead to intentional insulin omission. The convenience and reduced invasiveness of inhaled insulin may improve adherence rates by removing some of the barriers that lead young people to skip doses.
The discreet nature of the inhaler also allows for more private administration in social settings, which may be particularly important for teenagers who are self-conscious about their diabetes. Rather than needing to find a private space for an injection or feeling conspicuous using an insulin pen at a restaurant table, adolescents can use the Afrezza inhaler quickly and inconspicuously.
Flexibility in Diabetes Management Regimens
Afrezza can be integrated into various diabetes management approaches. It can be used as part of a traditional basal-bolus regimen, replacing injectable mealtime insulin while continuing with a long-acting basal insulin. For patients using insulin pumps who want to reduce their reliance on the device, Afrezza could potentially be used for mealtime coverage while maintaining pump-delivered basal insulin, though this approach would need to be carefully evaluated and monitored by healthcare providers.
The flexibility to adjust dosing based on meal size and composition, combined with the rapid onset and offset of action, may allow for more responsive diabetes management that adapts to the variable lifestyle patterns typical of childhood and adolescence.
Important Considerations and Limitations
While Afrezza offers promising advantages for pediatric diabetes management, it is not without limitations and considerations that must be carefully evaluated by healthcare providers, patients, and families.
Contraindications: Respiratory Disease Concerns
The most significant limitation of Afrezza is its contraindication in patients with chronic lung disease. Acute bronchospasm has been observed in Afrezza-treated patients with asthma and COPD · Afrezza is contraindicated in patients with chronic lung disease such as asthma or COPD · Before initiating Afrezza, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients.
This contraindication is particularly relevant in pediatric populations, as asthma is one of the most common chronic conditions affecting children. According to various epidemiological studies, asthma affects approximately 5-10% of children in developed countries, meaning a significant proportion of pediatric diabetes patients would not be candidates for Afrezza therapy.
The requirement for baseline spirometry testing before initiating Afrezza adds an additional step to the treatment initiation process. Healthcare providers must carefully screen patients for any history of respiratory symptoms, conduct thorough physical examinations, and perform pulmonary function testing to ensure that Afrezza is safe for a particular patient. Ongoing monitoring of lung function is also recommended for patients using Afrezza.
Proper Inhalation Technique: A Critical Success Factor
The effectiveness of Afrezza is highly dependent on proper inhalation technique. Unlike injectable insulin, where the dose is reliably delivered regardless of technique (assuming proper injection practices), inhaled insulin requires the patient to perform a specific breathing maneuver to ensure adequate drug delivery to the lungs.
For younger children, particularly those at the lower end of the approved age range (4-17 years), mastering the inhalation technique may present challenges. Healthcare providers must invest time in training patients and families on proper inhaler use, and regular assessment of technique is necessary to ensure ongoing effectiveness. Poor inhalation technique can result in inadequate insulin delivery, leading to suboptimal glucose control.
The cognitive and physical development of young children must be considered when determining whether a particular patient is capable of using the inhaler correctly and consistently. Some children may not have the coordination or understanding necessary to use the device effectively, making injectable insulin a more appropriate choice despite the advantages of needle-free delivery.
Dosing Considerations and Bioequivalence
Afrezza dosing is not directly equivalent to injectable insulin dosing, which can create confusion during the transition from injectable to inhaled insulin. The cartridges come in fixed doses (4, 8, and 12 units), and determining the appropriate Afrezza dose to replace a given amount of injectable insulin requires careful calculation and adjustment based on individual patient response.
This lack of direct bioequivalence means that patients transitioning to Afrezza require close monitoring and dose titration to achieve optimal glucose control. The fixed-dose cartridges also provide less flexibility than injectable insulin, which can be dosed in single-unit increments. For young children requiring very small insulin doses, this may limit the precision of dosing.
Limited Long-Term Safety Data in Pediatric Populations
While the INHALE-1 study provides valuable 26-week safety and efficacy data, with extension data out to 52 weeks, the long-term effects of chronic inhaled insulin use in growing children and adolescents remain to be fully elucidated. The developing lungs of children may respond differently to chronic insulin exposure than adult lungs, and longer-term studies will be necessary to fully characterize the safety profile.
Questions about the potential impact on lung growth and development, the effects of years of daily insulin inhalation, and the long-term pulmonary function outcomes in pediatric users will require ongoing post-marketing surveillance and long-term follow-up studies. Parents and healthcare providers must weigh the known benefits against these uncertainties when making treatment decisions.
Cost and Insurance Coverage Considerations
The cost of Afrezza and the extent of insurance coverage for this newer therapy may present barriers to access for some families. Inhaled insulin has historically been more expensive than traditional injectable insulin, and insurance companies may require prior authorization or step therapy (trying less expensive options first) before approving coverage for Afrezza.
For families already struggling with the financial burden of diabetes management—including the costs of continuous glucose monitors, test strips, basal insulin, and other supplies—the additional expense of Afrezza may be prohibitive. Healthcare providers must consider the economic realities facing their patients when recommending treatment options and work with families to navigate insurance coverage and patient assistance programs.
Comparing Afrezza to Other Pediatric Diabetes Treatment Options
To fully appreciate the potential role of Afrezza in pediatric diabetes management, it’s helpful to consider how it compares to other available treatment modalities.
Multiple Daily Injections (MDI)
The traditional basal-bolus regimen using multiple daily injections remains the most common approach to intensive insulin therapy in pediatric type 1 diabetes. This typically involves one or two daily injections of long-acting basal insulin (such as insulin glargine or insulin degludec) plus rapid-acting insulin injections before each meal and for correction of high blood glucose.
MDI offers precise dosing flexibility, with the ability to adjust insulin in single-unit or even half-unit increments. The pharmacokinetics and pharmacodynamics of injectable insulins are well-established, and healthcare providers have decades of experience with these medications. However, MDI requires multiple daily needle sticks, which can be burdensome and anxiety-provoking for children.
Afrezza could potentially replace the mealtime injections in an MDI regimen while maintaining injectable basal insulin, reducing the number of daily injections from 4-6 or more down to just 1-2 for basal insulin. This hybrid approach might offer an optimal balance of convenience and clinical effectiveness for some patients.
Insulin Pump Therapy
Insulin pumps deliver rapid-acting insulin continuously throughout the day via a small catheter inserted under the skin. Pumps offer the advantage of eliminating multiple daily injections, as the infusion site only needs to be changed every 2-3 days. They also provide very precise dosing and the ability to program different basal rates for different times of day.
However, pumps require wearing a device 24/7, which some children and adolescents find burdensome or stigmatizing. The infusion sites can become irritated or infected, and pump malfunctions can lead to dangerous hyperglycemia or diabetic ketoacidosis. Pumps are also expensive and require significant training and ongoing technical support.
For patients who dislike wearing a pump but want to avoid multiple daily injections, Afrezza might offer an appealing middle ground. However, pumps integrated with continuous glucose monitors in automated insulin delivery systems currently represent the most advanced technology for diabetes management, offering features that Afrezza cannot match.
Automated Insulin Delivery (AID) Systems
The newest frontier in diabetes technology is automated insulin delivery systems, sometimes called “artificial pancreas” systems or hybrid closed-loop systems. These integrate insulin pumps with continuous glucose monitors and use algorithms to automatically adjust insulin delivery based on real-time glucose readings.
AID systems have shown impressive results in improving glucose control and reducing hypoglycemia while decreasing the burden of diabetes management. They represent the current state-of-the-art in diabetes technology and are increasingly being adopted in pediatric populations.
Afrezza cannot currently be integrated into automated insulin delivery systems, which limits its appeal for families seeking the most technologically advanced diabetes management approach. However, for patients who prefer not to use pump therapy or who are not candidates for AID systems, Afrezza offers a valuable alternative that still provides significant advantages over traditional MDI.
Patient Selection: Who Are the Ideal Candidates for Afrezza?
Not every child with diabetes will be an appropriate candidate for Afrezza therapy. Healthcare providers must carefully consider multiple factors when determining whether inhaled insulin is suitable for a particular patient.
Age and Developmental Considerations
While the INHALE-1 study included children as young as 4 years old, the practical ability of very young children to use the inhaler correctly must be assessed on an individual basis. Older children and adolescents who can understand and follow instructions about proper inhalation technique are more likely to use the device successfully.
Cognitive development, maturity level, and willingness to take responsibility for diabetes management should all factor into the decision. Some younger children may do better with injectable insulin administered by parents or caregivers, while older children seeking more independence might thrive with the autonomy that Afrezza provides.
Respiratory Health Status
As previously discussed, any history of asthma, chronic obstructive pulmonary disease, or other chronic lung conditions represents an absolute contraindication to Afrezza use. Even patients with a history of reactive airway disease or frequent respiratory infections should be carefully evaluated before considering inhaled insulin.
Baseline pulmonary function testing is mandatory before initiating Afrezza, and patients should be monitored for any respiratory symptoms during treatment. Any decline in lung function or development of respiratory symptoms should prompt immediate reevaluation of the appropriateness of continuing Afrezza therapy.
Lifestyle and Psychosocial Factors
Patients who have significant needle phobia or who have demonstrated poor adherence to injectable insulin due to injection avoidance may be particularly good candidates for Afrezza. The psychological benefits of needle-free delivery may translate into improved adherence and better overall diabetes management for these individuals.
Adolescents who are self-conscious about their diabetes and reluctant to inject insulin in social settings might find the discreet nature of the inhaler appealing. Athletes who need rapid insulin action around training and competition might benefit from Afrezza’s pharmacokinetic profile.
Conversely, patients who are already achieving excellent glucose control with their current regimen and who don’t have significant issues with injections may not need to switch to Afrezza. The principle of “if it’s not broken, don’t fix it” applies—there’s no need to change a successful treatment approach simply because a new option is available.
Family Support and Resources
Successful use of Afrezza requires adequate family support, education, and resources. Families must be willing and able to learn proper inhaler technique, monitor for potential side effects, and work closely with their healthcare team to optimize dosing. Access to diabetes education and regular follow-up care is essential.
Financial resources and insurance coverage must also be considered. Families should verify insurance coverage and understand out-of-pocket costs before committing to Afrezza therapy. Patient assistance programs may be available for eligible families who face financial barriers to access.
Practical Aspects of Using Afrezza in Children
For families considering Afrezza for their child, understanding the practical aspects of using inhaled insulin is essential for making an informed decision and ensuring successful implementation.
The Afrezza Inhaler Device
The Afrezza inhaler is a small, portable device that is easy to carry and use discreetly. It consists of a reusable inhaler body and single-use cartridges containing the insulin powder. To use Afrezza, the patient inserts a cartridge into the inhaler, places the mouthpiece in their mouth, and inhales deeply to draw the insulin powder into their lungs.
The device does not require batteries or charging, making it simpler than many diabetes technology devices. However, proper storage of the insulin cartridges is important—they should be kept at room temperature and protected from moisture and extreme temperatures.
Dosing and Timing
Afrezza should be administered at the beginning of a meal, which differs from some injectable rapid-acting insulins that may be given 15-20 minutes before eating. The rapid onset of action means that insulin activity coincides closely with the rise in blood glucose from food absorption.
Determining the appropriate dose requires working closely with the healthcare team. The conversion from injectable insulin to Afrezza is not one-to-one, and dose adjustments based on blood glucose monitoring and continuous glucose monitor data are typically necessary during the transition period.
The fixed-dose cartridges (4, 8, and 12 units) can be combined to achieve the desired dose. For example, a patient needing 16 units could use one 12-unit cartridge and one 4-unit cartridge. This requires two separate inhalations, which may be less convenient than a single injection but still avoids needle sticks.
Integration with Continuous Glucose Monitoring
Afrezza can and should be used in conjunction with continuous glucose monitoring (CGM) systems. CGM provides real-time glucose data that can help patients and families make informed decisions about Afrezza dosing and timing. The rapid onset and offset of Afrezza make CGM particularly valuable, as it allows users to see how quickly their glucose responds to the inhaled insulin and make adjustments as needed.
The combination of Afrezza for mealtime insulin coverage and CGM for glucose monitoring represents a middle ground between traditional MDI and fully automated insulin delivery systems—offering significant technological support without requiring pump therapy.
Managing Special Situations
Certain situations require special consideration when using Afrezza. During illness, particularly respiratory illnesses, patients may need to temporarily switch back to injectable insulin. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking. Diabetic ketoacidosis requires intravenous or subcutaneous insulin administration, not inhaled insulin.
For children participating in sports or other vigorous physical activity, the rapid onset and offset of Afrezza may require different dosing strategies compared to injectable insulin. Working with a diabetes care team experienced in sports management is important for optimizing insulin dosing around exercise.
The Broader Context: Evolution of Diabetes Treatment
The potential approval of Afrezza for pediatric use represents part of a broader evolution in diabetes treatment that has accelerated dramatically over the past two decades. Understanding this context helps appreciate the significance of inhaled insulin as one option among an expanding array of treatment modalities.
From Animal Insulin to Modern Analogs
The history of insulin therapy spans over a century, beginning with the extraction of insulin from animal pancreases in the 1920s. This discovery transformed type 1 diabetes from a rapidly fatal disease to a manageable chronic condition. However, early insulin preparations were crude, unpredictable, and required multiple daily injections.
The development of recombinant human insulin in the 1980s represented a major advance, followed by the creation of rapid-acting and long-acting insulin analogs in the 1990s and 2000s. These analogs offered more predictable pharmacokinetics and improved flexibility in dosing compared to older insulin preparations.
Afrezza represents the next step in this evolution—not just a new insulin formulation, but an entirely different delivery mechanism that challenges the century-old paradigm of injected insulin.
The Technology Revolution in Diabetes Care
Parallel to advances in insulin formulations, diabetes technology has undergone a revolution. Continuous glucose monitors have largely replaced fingerstick blood glucose testing for many patients, providing real-time glucose data and trend information that enables more informed decision-making. Insulin pumps have evolved from basic infusion devices to sophisticated systems with multiple basal rates, bolus calculators, and integration with CGM.
The most recent advance—automated insulin delivery systems—represents a quantum leap forward, using algorithms to automatically adjust insulin delivery based on CGM data. These systems have shown remarkable success in improving glucose control while reducing hypoglycemia and decreasing the burden of diabetes management.
Afrezza fits into this landscape as a complementary option rather than a replacement for advanced technology. Some patients will prefer the simplicity of inhaled insulin over the complexity of pump therapy, while others will choose the automation and precision of AID systems. The expanding array of options allows for more personalized diabetes care tailored to individual preferences and needs.
The Importance of Patient Choice and Shared Decision-Making
One of the most important developments in modern diabetes care is the recognition that there is no single “best” treatment approach for all patients. Different individuals have different priorities, preferences, and circumstances that influence which treatment modality will work best for them.
Shared decision-making—a collaborative process in which healthcare providers and patients work together to make treatment decisions based on clinical evidence and patient preferences—has become the standard of care in diabetes management. The availability of Afrezza as an option for pediatric patients expands the menu of choices available during these discussions, allowing families to select an approach that aligns with their values and lifestyle.
Future Directions: Research and Development
The INHALE-1 study represents an important milestone, but it is not the end of research into inhaled insulin for pediatric populations. Ongoing and future studies will continue to refine our understanding of how best to use Afrezza in children and adolescents.
Long-Term Safety and Efficacy Studies
Extended follow-up of pediatric patients using Afrezza will be essential for understanding the long-term safety profile of inhaled insulin. Studies tracking pulmonary function, growth and development, and diabetes outcomes over years rather than months will provide valuable data to guide clinical practice.
Post-marketing surveillance studies mandated by regulatory agencies will collect real-world data on Afrezza use in diverse pediatric populations, potentially identifying rare adverse events or subgroups of patients who benefit particularly from or experience problems with inhaled insulin.
Comparative Effectiveness Research
Head-to-head comparisons of Afrezza with other treatment modalities—including different MDI regimens, various insulin pump systems, and automated insulin delivery—will help clarify the relative advantages and disadvantages of each approach. These studies should examine not only glycemic outcomes but also quality of life, treatment satisfaction, adherence, and cost-effectiveness.
Understanding which patients benefit most from Afrezza versus other options will enable more targeted recommendations and improve outcomes by matching patients with the most appropriate treatment approach for their individual circumstances.
Technological Integration
Future developments might include better integration of Afrezza with diabetes technology. While inhaled insulin cannot be delivered through an automated system in the same way as pump-delivered insulin, decision support tools could help patients determine appropriate Afrezza doses based on CGM data, carbohydrate intake, and other factors.
Smart inhaler devices that track usage and communicate with diabetes management apps could improve adherence monitoring and provide valuable data to healthcare providers. Such innovations could enhance the utility of Afrezza and make it more competitive with advanced diabetes technology systems.
Expanding Indications and Populations
Research into the use of Afrezza in specific pediatric populations—such as very young children, adolescents with type 2 diabetes, or patients with specific comorbidities—will help define the full scope of appropriate use. Studies in newly diagnosed patients, such as the recently initiated INHALE-1st trial, will explore whether starting with inhaled insulin from diagnosis offers advantages over traditional approaches.
Healthcare Provider Perspectives and Implementation
The successful integration of Afrezza into pediatric diabetes care will require education and support for healthcare providers who will be prescribing and managing this therapy.
Training and Education Needs
Pediatric endocrinologists, diabetes educators, and other members of the diabetes care team will need training on the appropriate use of Afrezza, including patient selection criteria, dosing strategies, inhaler technique instruction, and management of potential side effects. Understanding the differences between inhaled and injectable insulin pharmacokinetics is essential for optimizing therapy.
Educational resources, including training modules, patient education materials, and clinical practice guidelines, will need to be developed and disseminated to support healthcare providers in offering Afrezza as a treatment option.
Clinical Practice Integration
Integrating Afrezza into clinical practice workflows will require consideration of several practical factors. Baseline pulmonary function testing must be incorporated into the evaluation process for patients being considered for Afrezza. Follow-up protocols should include periodic reassessment of inhaler technique and monitoring for respiratory symptoms.
Diabetes care teams will need to develop protocols for transitioning patients from injectable to inhaled insulin, including dose conversion guidelines and monitoring strategies during the transition period. Communication between team members—physicians, nurse practitioners, diabetes educators, and dietitians—is essential for coordinated care.
Addressing Barriers to Adoption
Several barriers may limit the adoption of Afrezza in pediatric practice. Healthcare provider unfamiliarity with inhaled insulin, concerns about respiratory safety, uncertainty about dosing conversions, and insurance coverage challenges may all impede uptake of this new therapy.
Addressing these barriers will require multifaceted efforts, including provider education, development of clinical decision support tools, advocacy for insurance coverage, and collection of real-world evidence demonstrating the safety and effectiveness of Afrezza in diverse pediatric populations.
Patient and Family Perspectives
Ultimately, the success of Afrezza in pediatric diabetes management will depend on whether patients and families find it to be a valuable addition to their treatment options. Understanding the perspectives of those living with diabetes is essential for appreciating the potential impact of inhaled insulin.
The Burden of Daily Injections
For families managing pediatric diabetes, the burden of multiple daily injections is a constant reality. Parents describe the emotional toll of causing pain to their children multiple times every day, the difficulty of restraining young children for injections, and the guilt associated with being the source of repeated discomfort.
Children and adolescents report that injections are one of the most challenging aspects of living with diabetes. The physical pain, the visible marks on their bodies, and the social awkwardness of needing to inject in front of others all contribute to the burden. For many families, the prospect of eliminating mealtime injections through the use of Afrezza represents a meaningful improvement in quality of life.
Balancing Benefits and Concerns
Families considering Afrezza must weigh the benefits of needle-free delivery against potential concerns about respiratory safety, the need for proper inhaler technique, and uncertainty about long-term effects. Some families may be eager to try a new approach that could reduce diabetes burden, while others may prefer to stick with familiar injectable insulin until more long-term data are available.
The decision-making process is highly individual and depends on family values, risk tolerance, the child’s age and maturity, and practical considerations like insurance coverage and access to diabetes care. Healthcare providers can support families by providing balanced information about the potential benefits and limitations of Afrezza, helping them make informed decisions that align with their priorities.
The Importance of Realistic Expectations
It’s important for families to have realistic expectations about what Afrezza can and cannot do. While it eliminates mealtime injections, it does not eliminate the need for basal insulin injections, blood glucose monitoring or CGM use, carbohydrate counting, or the many other aspects of diabetes management. Afrezza is not a cure for diabetes, nor does it make diabetes management effortless.
However, for families struggling with injection-related challenges, Afrezza may provide meaningful relief from one of the most burdensome aspects of diabetes care. Setting appropriate expectations—understanding both the potential benefits and the limitations—is essential for treatment satisfaction and success.
Global Perspectives and Access Issues
While this article has focused primarily on the U.S. regulatory pathway and clinical context, it’s important to consider the global implications of inhaled insulin for pediatric diabetes management.
International Availability
It is also approved for use in India and Brazil and is recognized within the American Diabetes Association’s Standards of Care as a treatment option for adults with diabetes. The availability of Afrezza varies considerably across different countries and healthcare systems. Regulatory approval processes, healthcare infrastructure, and economic factors all influence whether and how quickly new diabetes treatments become available in different parts of the world.
For pediatric populations in low- and middle-income countries, where access to even basic insulin and diabetes supplies can be challenging, advanced therapies like inhaled insulin may remain out of reach for the foreseeable future. Addressing these global disparities in diabetes care access remains a critical priority for the international diabetes community.
Health Equity Considerations
Even within wealthy countries like the United States, significant disparities exist in access to advanced diabetes treatments. Socioeconomic factors, insurance coverage, geographic location, and healthcare system navigation challenges all affect whether families can access newer therapies like Afrezza.
Ensuring equitable access to inhaled insulin for all children who could benefit—regardless of their family’s economic circumstances or insurance status—will require attention to pricing, insurance coverage policies, patient assistance programs, and healthcare system factors that create barriers to access.
Conclusion: A New Chapter in Pediatric Diabetes Care
The potential approval of Afrezza for pediatric use represents a significant milestone in the ongoing evolution of diabetes treatment. After more than a century of insulin therapy delivered primarily through injections, the prospect of a needle-free option for children and adolescents offers hope for reducing one of the most burdensome aspects of diabetes management.
The INHALE-1 study has provided important evidence supporting the safety and efficacy of inhaled insulin in pediatric populations. Notably, in the modified ITT analysis, which excluded the single nonadherent patient, Afrezza was shown to be noninferior to multiple daily injections of rapid acting insulin analog (between-group difference: 0.370%). The comparable lung function parameters between treatment groups offer reassurance about respiratory safety over the 26-week study period.
However, Afrezza is not a panacea for all the challenges of pediatric diabetes management. It has important limitations, including contraindications in patients with respiratory disease, the need for proper inhalation technique, dosing considerations, and limited long-term safety data in children. Careful patient selection and ongoing monitoring are essential for safe and effective use.
The decision to use Afrezza should be made through shared decision-making between healthcare providers, patients, and families, taking into account individual circumstances, preferences, and priorities. For some children and adolescents, particularly those with significant needle anxiety or poor adherence related to injection avoidance, Afrezza may offer meaningful benefits. For others, traditional injectable insulin or advanced diabetes technology systems may be more appropriate.
As we await the FDA’s decision on the pediatric indication for Afrezza, with a target action date of May 29, 2026, the diabetes community watches with interest and hope. If approved, Afrezza will expand the menu of treatment options available for pediatric diabetes management, offering families another tool in their efforts to help their children live healthy, fulfilling lives with diabetes.
The journey toward optimal diabetes care continues, with innovations like inhaled insulin representing important steps forward. While challenges remain—including ensuring equitable access, generating long-term safety data, and integrating new therapies into clinical practice—the expanding array of treatment options reflects the dedication of researchers, clinicians, industry partners, and patient advocates to improving the lives of people living with diabetes.
For families currently managing pediatric diabetes, staying informed about emerging treatment options like Afrezza is important. Discussing these options with your diabetes care team, understanding the potential benefits and limitations, and making decisions that align with your family’s values and circumstances will help ensure the best possible outcomes for your child.
Additional information about Afrezza, including prescribing information and safety data, can be found at www.afrezza.com. Families seeking support and information about pediatric diabetes management can connect with organizations like the Juvenile Diabetes Research Foundation (JDRF), the American Diabetes Association, and Beyond Type 1, which offer educational resources, community support, and advocacy for people living with diabetes and their families.
As we look to the future, the continued development of innovative diabetes treatments and technologies offers hope for progressively reducing the burden of this challenging condition. Each advance—whether a new insulin formulation, an improved delivery device, or a more sophisticated automated system—brings us closer to the ultimate goal of a cure for diabetes. Until that day arrives, expanding treatment options like Afrezza represent important progress in helping children and adolescents with diabetes live healthier, happier lives.